10:08 EDT Cardiol falls 14% to $1.16 after myocarditis study results
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL:
- Cardiol data readout positive and not priced in, says H.C. Wainwright
- Cardiol Therapeutics announces Phase II ARCHER results in myocarditis
- Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis
- Positive Outlook for Cardiol Therapeutics Amid ARCHER Trial Progress and Market Potential
- Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis